Andrew J Weickhardt

Summary

Affiliation: University of Colorado Denver
Country: USA

Publications

  1. pmc Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer
    Andrew J Weickhardt
    Department of Medicine, Division of Medical Oncology, University of Colorado Cancer Center, Colorado 80045, USA
    J Thorac Oncol 7:1807-14. 2012
  2. pmc A phase I/II study of erlotinib in combination with the anti-insulin-like growth factor-1 receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced non-small cell lung cancer
    Andrew Weickhardt
    University of Colorado Cancer Center, Aurora, Colorado 80045, USA
    J Thorac Oncol 7:419-26. 2012
  3. doi Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer
    Andrew J Weickhardt
    Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA
    Cancer 118:5302-9. 2012
  4. pmc Diagnostic assays for identification of anaplastic lymphoma kinase-positive non-small cell lung cancer
    Andrew J Weickhardt
    Division of Medical Oncology, University of Colorado Cancer Center, Anschutz Medical Campus, Aurora, Colorado, USA
    Cancer 119:1467-77. 2013
  5. pmc Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients
    Andrew J Weickhardt
    Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA
    Cancer 119:2383-90. 2013
  6. pmc Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer
    Robert C Doebele
    Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA
    Cancer 118:4502-11. 2012
  7. pmc Drug-induced reduction in estimated glomerular filtration rate in patients with ALK-positive non-small cell lung cancer treated with the ALK inhibitor crizotinib
    Evelyn M Brosnan
    Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado
    Cancer 120:664-74. 2014
  8. pmc Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer
    Robert C Doebele
    Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado 80209, USA
    Clin Cancer Res 18:1472-82. 2012
  9. doi ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers
    Dara L Aisner
    University of Colorado School of Medicine Anschutz Medical Campus, 12801 East 17th Avenue, L18 8118, Mail Stop 8117, Aurora, CO 80045
    Mol Cancer Res 12:111-8. 2014

Detail Information

Publications9

  1. pmc Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer
    Andrew J Weickhardt
    Department of Medicine, Division of Medical Oncology, University of Colorado Cancer Center, Colorado 80045, USA
    J Thorac Oncol 7:1807-14. 2012
    ....
  2. pmc A phase I/II study of erlotinib in combination with the anti-insulin-like growth factor-1 receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced non-small cell lung cancer
    Andrew Weickhardt
    University of Colorado Cancer Center, Aurora, Colorado 80045, USA
    J Thorac Oncol 7:419-26. 2012
    ....
  3. doi Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer
    Andrew J Weickhardt
    Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA
    Cancer 118:5302-9. 2012
    ..The objective of this study was to document the differences in testosterone (T) levels between crizotinib-treated and noncrizotinib-treated patients with metastatic nonsmall cell lung cancer (NSCLC)...
  4. pmc Diagnostic assays for identification of anaplastic lymphoma kinase-positive non-small cell lung cancer
    Andrew J Weickhardt
    Division of Medical Oncology, University of Colorado Cancer Center, Anschutz Medical Campus, Aurora, Colorado, USA
    Cancer 119:1467-77. 2013
    ..In the current review, the authors summarize the diagnostic tests available, or likely to become available, that could be used to identify patients with ALK-positive NSCLC, highlighting the pros and cons of each...
  5. pmc Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients
    Andrew J Weickhardt
    Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA
    Cancer 119:2383-90. 2013
    ..The detailed etiology of the effect, its symptomatic significance, and the effectiveness of subsequent testosterone replacement have not been previously reported...
  6. pmc Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer
    Robert C Doebele
    Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA
    Cancer 118:4502-11. 2012
    ..It is hypothesized that the dominant oncogene in NSCLC would be associated with distinct patterns of metastatic spread in NSCLC at the time of diagnosis...
  7. pmc Drug-induced reduction in estimated glomerular filtration rate in patients with ALK-positive non-small cell lung cancer treated with the ALK inhibitor crizotinib
    Evelyn M Brosnan
    Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado
    Cancer 120:664-74. 2014
    ..To the best of the authors' knowledge, the renal side effects of crizotinib have not been investigated previously...
  8. pmc Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer
    Robert C Doebele
    Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado 80209, USA
    Clin Cancer Res 18:1472-82. 2012
    ..This study aimed to define molecular mechanisms of resistance to crizotinib in patients with ALK(+) non-small cell lung cancer (NSCLC)...
  9. doi ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers
    Dara L Aisner
    University of Colorado School of Medicine Anschutz Medical Campus, 12801 East 17th Avenue, L18 8118, Mail Stop 8117, Aurora, CO 80045
    Mol Cancer Res 12:111-8. 2014
    ..Implications: ROS1 and ALK fusions occur in colorectal cancer and may have substantial impact in therapy selection...